You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 5,683,905

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,683,905

Title:	Vectors and cell lines capable of correctly splicing exon regions
Abstract:	A recombinant DNA vector is provided that expresses exons of genomic DNA fragments that are inserted into the vector. The vector contains a promoter and a genomic DNA fragment so characterized and configured that the vector, upon transcription in a transfected eukaryotic cell culture, expresses the corresponding RNA segment of the genomic DNA fragment free of any intron.
Inventor(s):	Capon; Daniel J. (San Mateo, CA), Lawn; Richard M. (San Francisco, CA), Vehar; Gordon A. (San Carlos, CA), Wood; William I. (San Mateo, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	08/448,171
Patent Claims:	1. A recombinant DNA vector which expresses exons of genomic DNA fragments inserted into the vector, which vector comprises: (1) a promoter operably linked to a splice donor site followed by a splice acceptor site and (2) a genomic DNA fragment inserted between said splice donor and splice acceptor sites, wherein the genomic DNA fragment comprises a splice acceptor site followed by a splice donor site, and wherein said vector, upon transcription in a transfected eukaryotic cell culture, expresses the corresponding RNA segment of said genomic DNA fragment free of any intron. 2. The vector of claim 1 wherein the genomic DNA fragment codes for a polypeptide of interest. 3. The vector of claim 2 wherein the polypeptide is human factor VIII. 4. A eukaryotic cell culture transfected with a vector according to claim 1. 5. pESVDA. 6. A eukaryotic cell culture transfected with a vector according to claim 5 .

Details for Patent 5,683,905

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.